3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Carcinoma, Non-Small-Cell Lung
2
Tracheal Diseases
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Laryngeal Diseases
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma, Adenoid Cystic
1
Advanced or Metastatic Solid Tumors
1
Interventions
Doxorubicin
5
pembrolizumab
4
Specimen Handling
4
Radiotherapy
4
Radiation
4
Nivolumab
4
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
CTLA-4 Antigen
3
Biopsy
3
cabozantinib
2
Ifosfamide
2
talimogene laherparepvec
1
regorafenib
1
peposertib
1
pazopanib
1
olaratumab
1
liposomal doxorubicin
1
futibatinib
1
fludarabine
1
eribulin
1
avelumab
1
aldesleukin
1
X-Rays
1
Trabectedin
1
Standard of Care
1
Quality of Life
1
Injections
1
Immune Checkpoint Inhibitors
1
Histamine H2 Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
Combined Modality Therapy
×
1 year
×
Clear all
No trials found.